Related Experiment Video
Updated: Jun 24, 2026

Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury
Published on: February 23, 2015
Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads
Vernon D Twede1, George Miljanich, Baldomero M Olivera
1Department of Biology, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112, USA.
Abstract:
The peptides in the venoms of predatory marine snails belonging to the genus Conus ('cone snails') have well-established therapeutic applications for the treatment of pain and epilepsy. This review discusses the neuroprotective and cardioprotective potential of four families of Conus peptides (conopeptides), including omega-conotoxins that target voltage-gated Ca2+ channels, conantokins that target NMDA receptors, mu-conotoxins that target voltage-gated Na+ channels, and kappa- and kappaM-conotoxins that target K+ channels. The diversity of Conus peptides that have already been shown to exhibit neuroprotective/cardioprotective activity suggests that marine snail venoms are a potentially rich source of drug leads with diverse mechanisms.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacogenomics: Identification of New Drug Targets
Heart Failure Drugs: Inotropic Agents
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
